# A Phase I Study of BR108 in Hematological Malignancies

> **NCT06018506** · PHASE1 · TERMINATED · sponsor: **BioRay Pharmaceutical Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** BR108 injection

## Key facts

- **NCT ID:** NCT06018506
- **Lead sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-18
- **Primary completion:** 2024-05-27
- **Final completion:** 2024-06-21
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Adjustment of Company R\&D strategy
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06018506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06018506, "A Phase I Study of BR108 in Hematological Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06018506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*